PERTH, Australia--(BUSINESS WIRE)--AION Diagnostics Inc, a nano-diagnostics company developing medical imaging agents, announced today positive preliminary results of a pilot study showing the high intravascular contrast enhancement of modified porous silicon (mpSi) in reduced dose amounts. The trialled intravascular contrast agent is based on the same formulation as AION’s Marking Agent, a medical device to be registered under the CE Mark in Europe and via the 510(K) route in the US.
